Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 252

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 252
---
44 — — — 44 Issuance of ordinary shares upon exercise of stock options2— 1 — — — 1 Share-based compensation expense— — 5,396 — — — 5,396 Net loss— — — — — (62,106)(62,106)Net unrealized gains on available-for-sale investments— — — 354 — — 354 Foreign currency translation adjustments— — — (614)— — (614)Balance, December 31, 202355,10310 432,402 (1,008)(180)(329,727)101,497 Issuance of ordinary shares under Employee Stock Purchase Plan45— 33 — — — 33 Issuance of ordinary shares upon exercise of stock options201— 194 — — — 194 Share-based compensation expense— — 6,728 — — — 6,728 Net loss— — — — — (15,628)(15,628)Net unrealized gains on available-for-sale investments— — — 12 — — 12 Foreign currency translation adjustments— — — (670)— — (670)Balance, December 31, 202455,349$10 $439,357 $(1,666)$(180)$(345,355)$92,166 

See accompanying Notes to Consolidated Financial Statements.

112

CONNECT BIOPHARMA HOLDINGS LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

Years Ended December 31,20242023Operating activities:Net loss$(15,628)$(62,106)Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation expense6,728 5,396 Depreciation and amortization660 720 Realized gain on available-for-sale investments— (1)Accretion of discounts on available-for-sale investments(123)(1,703)Impairment of property and equipment232 — Loss on disposal of property and equipment9 — Loss on disposal of land use rights— 102 Change in operating assets and liabilities:Accounts receivable, net(789)— Prepaid expenses and other assets1,786 3,694 Other non